Bone Biologics Files 8-K for Undisclosed 'Other Event'

TL;DR

**Bone Biologics filed an 8-K for an 'Other Event' on Jan 10, but the details are missing, so keep an eye out for more info.**

AI Summary

Bone Biologics Corp. filed an 8-K on January 12, 2024, reporting an "Other Event" that occurred on January 10, 2024. While the filing itself is brief and doesn't detail the specific event, it indicates a change or development that the company deemed significant enough to report to the SEC. For investors, this matters because "Other Events" can sometimes signal important, yet undisclosed, corporate actions or developments that could impact the stock price, making further investigation into the nature of this event crucial.

Why It Matters

This filing signals an undisclosed corporate event that could be significant, potentially impacting Bone Biologics Corp.'s future operations or financial standing, and thus its stock value.

Risk Assessment

Risk Level: medium — The lack of specific details regarding the 'Other Event' creates uncertainty, which can be a medium risk for investors as the nature of the event is unknown.

Analyst Insight

A smart investor would monitor Bone Biologics Corp. for subsequent filings or press releases that might disclose the specifics of the 'Other Event' to assess its potential impact.

Key Players & Entities

• Bone Biologics Corp. (company) — the registrant filing the 8-K
• January 10, 2024 (date) — date of the earliest event reported
• January 12, 2024 (date) — date the 8-K was filed
• 001-40899 (other) — Commission File Number for Bone Biologics Corp.

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
• $750,000 — nt, the Company will pay the plaintiffs $750,000 in cash within 20 business days after t
• $400,000 — rance carrier's portion of the claim is $400,000 less certain retention amounts. The Agr

Filing Documents

• form8-k.htm (8-K) — 47KB
• 0001493152-24-002233.txt ( ) — 260KB
• bblg-20240110.xsd (EX-101.SCH) — 4KB
• bblg-20240110_def.xml (EX-101.DEF) — 26KB
• bblg-20240110_lab.xml (EX-101.LAB) — 36KB
• bblg-20240110_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On January 10, 2024, Bone Biologics Corporation (the "Company") entered into a Settlement Agreement and Mutual General Release (the "Agreement") with Drs. Bessie (Chia) Soo and Kang (Eric) Ting, on the one hand (the "plaintiffs"), and Stephen LaNeve on the other hand (together with the Company, the "defendants"), in settlement of the claims for breach of contract and tortious interference with contract against the defendants filed in the United States District Court for the District of Massachusetts (the "Court") as previously described in the Company's periodic reports under the Securities Exchange Act of 1934, as amended. The Agreement is effective as of January 9, 2024. The Company believes that a settlement of the claim is in the best interests of the Company and its stockholders after considering the facts and circumstances surrounding the proposed settlement, including: (i) the strengths and weaknesses of the claims asserted by plaintiffs and the defendants' defenses; (ii) the potential recovery from the claims asserted; (iii) the time, expense, risks, and uncertainties of continued litigation; (iv) the effect on the Company of continued litigation; and (v) the anticipated benefits that the proposed settlement affords the Company. The Company had certain indemnification obligations to Mr. LaNeve arising out of actions taken in connection with his service to the Company. Under the Agreement, the Company will pay the plaintiffs $750,000 in cash within 20 business days after the date the Agreement was executed. The Company's insurance carrier's portion of the claim is $400,000 less certain retention amounts. The Agreement provides that the parties to the Agreement will file a joint stipulation to dismiss the action with prejudice with the Court and the Company expects the action to be dismissed by the Court. Forward Looking Statements Except for the factual statements made herein, information contained in this report consists of fo

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: January 12, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR